CAR T Autoimmune

In development for the treatment of autoimmune diseases:

DEEPER B CELL DEPLETION IS POSSIBLE
CAR T CELL THERAPY COULD MAKE THE DIFFERENCE

Could a one-time infusion* of CAR T cell therapy
change the way autoimmune diseases are treated?²

CAR T cell therapy is being studied in a range of autoimmune diseases, including systemic lupus erythematosus (and lupus nephritis), idiopathic inflammatory myopathy, systemic sclerosis, multiple sclerosis, and myasthenia gravis.^3-5

The need for deeper B cell depletion

Superficial B cell depletion is not enough. CAR T cells may make deeper B cell depletion possible.^6,7

What is CAR T cell therapy?

Autologous CAR T cell therapy is a type of immunotherapy utilizing a patient’s own T cells.^7,8

Treatment steps and one-time infusion

There are 3 main steps to receiving CAR T cell therapy.^2,6

Explore ongoing BMS CAR T clinical trials in autoimmune disease.^3-5
Trials are open and enrolling participants.

Rheumatology (SLE [and LN], IIM, SSc)

Neuroinflammatory (MS, MG)

*Treatment process includes leukapheresis, manufacturing, administration, and adverse event monitoring.²
CAR=chimeric antigen receptor; IIM=idiopathic inflammatory myopathies; LN=lupus nephritis; MG=myasthenia gravis; MS=multiple sclerosis; SLE=systemic lupus erythematosus; SSc=systemic sclerosis.

References:

Tur C, Eckstein M, Velden J, et al. CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann Rheum Dis. 2025;84(1):106-114.
Beaupierre A, Lundberg R, Marrero L, Jain M, Wang T, Alencar MC. Management across settings: an ambulatory and community perspective for patients undergoing CAR T-cell therapy in multiple care settings. Clin J Oncol Nurs. 2019;23(2):27-34.
Clinicaltrials.gov. NCT05869955. Accessed March 12, 2025.
Data on file. REF-00068-466. Princeton, NJ: Bristol-Myers Squibb Company; 2024.
Clinicaltrials.gov. NCT06220201. Accessed March 13, 2025.
Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease – a case series with follow-up. N Engl J Med. 2024;390(8):687-700.
Taubmann J, Müller F, Mutlu MY, et al. CD19 chimeric antigen receptor T cell treatment: unraveling the role of B cells in systemic lupus erythematosus. Arthritis Rheumatol. 2024;76(4):497-504.
Maus MV, Levine BL. Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist. 2016;21(5):608-617.